Founded in 2001, Cardiac Dimensions has developed a way to address cardiovascular conditions with its Carillon Mitral Contour System, a non-surgical device that treats a form of congestive heart failure called mitral valve regurgitation, which affects how the heart properly pumps out blood. It’s the most common type of heart valve disorder.
The company will use the fresh funds to expand its commercial activities in Europe and begin a series of clinical trials with up to 20 hospitals. It will also open up a new facility in Australia to provide access to Asia Pacific markets.
Cardiac Dimensions is the latest Seattle-based biotech organization to bring in funding this year. Adaptive Biotechnologies raised $105 million earlier this month, which came just a day after the Fred Hutchinson Cancer Research Center announced a $20 million donation from the family of Amazon.com CEO Jeff Bezos. Then there’s Juno Therapeutics, a Seattle startup spun out of the Fred Hutch, the Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute, which raised a hefty $145 million series A round in January.